Core Viewpoint - Hutchison China MediTech Limited (HCM) has seen its stock rise over 3%, currently trading at 24.46 HKD, with a trading volume of 65.52 million HKD, following the announcement of an upcoming investor meeting to discuss key R&D and business progress [1] Group 1: Company Developments - HCM will hold an investor meeting on October 31, 2025, to share the latest advancements in innovative cancer and immune disease treatments [1] - The meeting will highlight the progress of HCM's next-generation antibody-drug conjugate (ATTC) platform and the latest developments of its late-stage pipeline candidates [1] - The first candidate drug from the ATTC platform, HMPL-A251, is a PAM-HER2 ATTC, which combines a highly selective and potent PI3K/PIKK inhibitor as an effective payload with a humanized anti-HER2 IgG1 antibody via a cleavable linker [1] Group 2: Clinical Development - Recent preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer Treatment [1] - HCM plans to advance HMPL-A251 into clinical development starting at the end of 2025, with initial studies aimed at evaluating the drug's performance across multiple tumor types with varying HER2 and PAM alteration statuses [1]

Core Viewpoint - Hutchison China MediTech Limited (HCM.US) shares rose over 2% pre-market, reaching $15, while its H-shares increased by 2.15% to HKD 23.76, following an investor meeting where the company shared updates on its innovative ATTC platform and product developments [1] Group 1: Company Developments - The company presented its first candidate drug HMPL-A251 from the ATTC platform, which demonstrated high selectivity and strong anti-tumor activity in various tumor cell lines during in vitro experiments [1] - Hutchison China MediTech plans to adopt a data-driven strategy to advance HMPL-A251 into clinical development starting at the end of 2025, with initial studies assessing the drug's performance across multiple tumor types with different HER2 and PAM alteration statuses [1]

致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法 ...

Core Viewpoint - The company is set to share its latest key research and business developments at an investor meeting on October 31, 2025, focusing on advancements in innovative cancer and immune disease treatments [1] Group 1: Research and Development Progress - The event will highlight the company's progress in its next-generation antibody-drug conjugate (ATTC) platform and the latest developments in its late-stage pipeline candidates [1] - The Chief Medical Officer emphasized the company's mission to address critical unmet medical needs in cancer and immune diseases, driving the commitment to advance innovative therapies [1] Group 2: Strategic Vision - The ATTC platform is expected to redefine precision treatment for cancer, supported by a robust product pipeline and collaborative strategies [1] - The company expresses confidence in its ability to provide transformative treatment options for patients globally in the fields of cancer and immune diseases [1]

Core Viewpoint - The company is focused on advancing innovative treatments for cancer and immune diseases, showcasing its latest developments in the ATTC platform and late-stage pipeline candidates [1] Group 1: R&D Progress - The company shared key advancements in its innovative cancer and immune disease treatments during an investor meeting [1] - The ATTC platform is expected to redefine precision treatment for cancer, addressing unmet medical needs in these fields [1] Group 2: Leadership Insights - Dr. Shi Ming, the company's R&D head and Chief Medical Officer, emphasized the mission to meet critical unmet medical needs in cancer and immune diseases [1] - The company is confident in its ability to provide transformative treatment options for patients globally, supported by a robust product pipeline and collaboration strategies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥舉辦最新研發進展投資者會議分享產品管線及業務進展 — 和黃醫藥介紹其創新ATTC平台，有望通過雙重作用機制為癌症精準治療帶來變革 — — 首個候選藥物HMPL-A251搭載選擇性PI3K/PIKK抑制劑有效載荷，在 臨床前研究中展現出令人鼓舞的療效與安全性 — 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）於2025年10月31日舉行的投資者會議中分享 最新關鍵研發和業務進展。此次活動重點展示了和黃醫藥在推進創新癌症和免疫疾病治療方面的最新進展，包括介 紹其新一代抗體靶向偶聯藥物（ 「ATTC」）平台，以及後期管線候選藥物的最新進展。 和黃醫藥研發負責人兼首席醫學官石明博士表示：「滿足癌症和免疫疾病領域關鍵未被滿足的醫學需求是和黃醫 藥的 ...

Core Insights - HUTCHMED has introduced its innovative Antibody-Targeted Therapy Conjugate (ATTC) platform, which aims to redefine precision oncology through a dual-mechanism of action [1][2] - The lead candidate HMPL-A251, a selective PI3K/PIKK inhibitor, has shown promising preclinical efficacy and safety, positioning HUTCHMED's late-stage pipeline for further development [1][4] - The company is making significant progress in global and China trials, including studies for fruquintinib, surufatinib, and fanregratinib, enhancing its late-stage pipeline [1][9] ATTC Platform and Lead Candidate - The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads, providing synergistic anti-tumor activity and improved safety profiles compared to traditional antibody-drug conjugates [2][3] - HMPL-A251 is designed to target the PAM signaling pathway, which is often associated with poor prognosis in various cancers, and aims to enhance targeted delivery while minimizing systemic exposure [3][4] - Preclinical data indicates that HMPL-A251 exhibits strong anti-tumor activity, particularly in HER2-positive tumors, and shows potential for improved efficacy compared to existing therapies like trastuzumab deruxtecan [4][5] Clinical Development Plans - HUTCHMED plans to advance HMPL-A251 into clinical development in late 2025, focusing on various cancer types with different HER2 and PAM alteration statuses [5] - The company aims to explore a broader range of antibody selections and payload options to enhance treatment outcomes and overcome resistance [6] Late-stage Program Updates - The company reported significant progress in late-stage programs, including the FRUSICA-2 study for fruquintinib, which demonstrated a progression-free survival of 22.2 months compared to 6.9 months with standard treatments [9] - Recruitment for the SANOVO study in first-line EGFR-mutated non-small cell lung cancer has been completed, with further studies for surufatinib and fanregratinib also advancing [9]

Core Points - HUTCHMED is hosting its 2025 R&D Day event to discuss its research and development strategies and performance [1] Group 1 - The presentation is led by David Ng, the Head of Investor Relations & Capital Strategies, indicating a focus on investor engagement [1] - Dr. Michael Shi, the CMO and Head of R&D, is introduced to present the details of the event, highlighting the importance of R&D in the company's future [1]

HUTCHMED (China) (NasdaqGS:HCM) Update Summary Company Overview - **Company**: HUTCHMED (China) - **Event**: 2025 R&D Day - **Date**: October 31, 2025 Key Industry and Company Insights 1. Antibody-Drug Conjugate (ADC) Development - HUTCHMED is focusing on a new platform called Antibody Target Therapy Conjugate (ATTC) which aims to improve the efficacy and safety of ADCs compared to traditional toxin-based ADCs [2][4][14] - The company presented its first candidate, A251, at the URTC meeting, highlighting its potential in cancer treatment [2][14] 2. Current ADC Landscape - There are currently 19 ADCs approved globally, but traditional toxin-based ADCs face challenges such as myelosuppression and hepatotoxicity [3][4] - HUTCHMED's ATTC platform is designed to target proteins essential for cancer growth, potentially overcoming the limitations of existing ADCs [3][4] 3. Targeting the PI3K/mTOR Pathway - The PI3K/AKT/mTOR pathway is a significant target due to its high mutation frequency in common cancers, such as breast and endometrial cancer [6][10] - HUTCHMED's approach includes using a PI3K/PIKK inhibitor (HMPL-606) as a payload in their ADCs, which shows promise in overcoming drug resistance [10][27] 4. Candidate A251 - A251 combines a HER2 antibody with a PI3K/PIKK inhibitor, showing robust anti-tumor activity in preclinical models [14][27] - The candidate has demonstrated a favorable safety profile compared to traditional small molecule therapies, with no significant body weight loss observed in animal models [22][27] 5. Clinical Development Plans - HUTCHMED has received FDA clearance for the IND of A251 and plans to initiate Phase 1 clinical trials targeting HER2 positive and low patient populations [27][29] - The company aims to explore combination therapies with chemotherapy in frontline settings [29] 6. Late-Stage Pipeline Updates - HUTCHMED's first approved product, FRUZAQLA, has shown a 25% increase in global sales, reaching $162 million [45] - The company is advancing multiple products, including MET inhibitors and SYK inhibitors, with several trials expected to report results in the coming year [34][45] 7. Market Opportunities - The HER2 positive patient population represents 15-20% of breast cancer cases, with HER2 low patients making up 40-50%, indicating a significant market opportunity for A251 [30][31] - The potential market size for HER2 negative breast cancer treatments is estimated at $5 billion, suggesting a broad application for HUTCHMED's therapies [31] 8. Future Prospects - HUTCHMED is optimistic about the ATTC platform's potential to address various tumor types and is exploring additional candidates for clinical development [32][46] - The company maintains a strong balance sheet and is looking for in-house and out-licensing opportunities to enhance growth [46] Additional Important Insights - The ATTC platform is expected to provide a competitive edge in combining therapies with traditional chemotherapy, which has been a challenge for existing ADCs [53] - HUTCHMED is also focusing on global development opportunities for its products, particularly in the context of regulatory agreements with the CDE [62][63] This summary encapsulates the key points from the HUTCHMED R&D Day, highlighting the company's innovative approaches in cancer treatment and its strategic plans for future growth.

Safe harbor statement & disclaimer R&D UPDATES October 31, 2025 HKEX: 13, Nasdaq / AIM:HCM The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. The performance and results of operations of the Group contained within this presentation are historical in nature, and past performance is no guarantee of future results of the Group. This presentation contains forward-looking statements w ...